PwC Final PPT.pptx pitch Deck presentation
- 1. Team QuattroVision IIM Lucknow Anubhav Choudhary | Pragati Saini | Sanskriti Kocher | Vaibhav Sharma
- 2. Major Drivers Executive Summary Revolutionizing the pharmaceutical sector through latest technological advancements. Industry Trends 3 – Year Roadmap Tech Integrations Attractive Markets for Entry Y1: Laying the Foundation Y2: Technological Advancements and Innovation Mfg. & Distribution Optimisation AI-driven Engagement Digital Ecosystem Dev Data-driven Operations SCM Resilience R&D Transformation Y3: Industry Leadership Continued Innovation Market domination & Expansion Sustainable Ops & Cost Control India is the most attractive for setting a manufacturing base Risks & challenges Competitive landscape Political stability & regulations Technology & economic conditions Logistics & transportation Other factors India Korea Brazil Saudi Arabia The Global Pharma industry is predicted to achieve a $2 trillion valuation by 2027 1. Advances in Tech solution 2. Expansion of product portfolios 3. Geopolitical considerations 4. New Modalities Value Chain Analysis Analyzed the value chain to identify growth opportunities & Strategies to implement tech-based solutions • Genomics & Proteomics to identify novel drugs; AI-ML to enhance drug discovery • Decentralized clinical trials using remote monitoring & wearable devices; Biomarkers for patients • Flexible manufacturing for personalized medicine • Cloud & blockchain to improve supply chain transparency • Digital platforms to engage with doctors; faster launches • Algorithm guided treatment decision & remote monitoring Tech Enabled patient lifecycle management Cloud migration & strategies to accelerate Ops Digitally engage e-pharmacy consultants
- 3. GLOBAL PHARMA MARKET Major Global Players Key Pharma Tech Trends … of pharma executives say these technologies will matter most in the next 5 years *Bain Insights Challenges Faced by Pharma Sector Need for qualified professionals Pricing Scrutiny Extended drug development timelines Regulations & Litigation Costs Supply Chain Disruptions Increasing Competition $2 Tn Projected Global Market for Medicines by 2027 8% Expected CAGR for the global pharma market xx Xx yy zz Pls add someone Industry Analysis (1/2): Analysis of key trends in the pharma market Pharma's rapid growth entails significant tech investments throughout the value chain
- 4. Trends Complexity Increased Risk Capability Capital Expenditur e Variable- cost increase Savings Opportunity Advantages in technology and user willingness Diffusion of individual player’s power Environmental, Social & governance expectations Geopolitical considerations Labor Market Challenges New Modalities New Work Expectations Pressure to innovate Rising Inflation Supply Chain Disruptions Degree of Impact High Medium Low Operations leaders are becoming more comfortable navigating a more complex ecosystem as they respond to increased operational complexity. Risks are increasing due to rising environmental, social, and governance (ESG) expectations and skills gaps, while new modalities and digital acceleration are also likely leading to a shift in capability requirements. This is necessitating reskilling and upskilling of staff, as well as a renewed focus on recruiting from outside of the pharma industry. Industry Analysis (2/2): Analysis of key trends in the pharma market Current trends add more cost, complexity, risk, with these forces compounding one another GLOBAL PHARMA MARKET
- 5. Strategic Planning : From CXO vision to Roadmap milestones Analysing CXO Insights & Pharma Industry Trends, Identifying Key Focus Areas to define Milestones Setting milestones based on key focus areas Insights from CXOs CEO CFO COO CTO CMO Building a Resilient supply chain Exploring New Markets and Opportunities Leveraging Tech for Innovation and Efficiency Effective Stakeholder Communication Addressing Rising Supply Chain Costs Streamlining Contract Management Financial Planning for Tech Investments Geopolitical Risk Analysis and Contingency Plans Profitability Analysis for Trade Flow Changes Target Audience Engagement (Doctors & Patients) Strong Brand Image via Modern Technologies Robust Digital Presence for Wider Consumer Base Effective Content Strategy and Automation Utilizing AI and ML for Marketing Advancements Enhancing Operational Efficiency with Technology Optimizing Distribution Channel Strategy Diversifying Manufacturing Base for Cost Savings Achieving 30% Revenue Growth Strategies AI Integration for Planning and Efficiency Harnessing New-Age Tech for Operational Solutions Data-Driven R&D and Drug Development Developing a Tech-Based Digital Ecosystem Aligning Tech Investments with Innovation Goals Staying Current with AI and ML Advancements Supply Chain Resilience and Diversification : Identify alternative sourcing locations outside China, Partner with diverse suppliers to reduce disruptions and Create a comprehensive risk assessment framework. Technology Integration and Data-driven operations : Invest in AI for efficient manufacturing, Implement predictive maintenance for uptime and establish data platforms for insights. Market expansion and Customer targeting : Enter emerging European markets , Develop AI-based care management for doctors and launched personalized campaigns for patients Digital ecosystem development : Create a tech based digital ecosystem , partner with tech startups for innovation and develop an AI-powered symptom checker for doctors to enhance diagnostic capabilities YEAR 1: Laying the Foundation YEAR 2: Technological Advancements and Innovation YEAR 3: Industry Leadership Research and Development transformation : Implement AI/ML in drug discovery and trials, Collaborate with research and start-ups and Optimize drug development with data AI-Enhanced Marketing and Customer Engagement: Use Generative AI/ML for targeted marketing. Personalize interactions with AI Manufacturing and Distribution Optimization: Expand manufacturing globally, Optimize supply chain with AI and real-time IoT monitoring Sustainable Operations and Cost Control : Implement eco-friendly practices, Explore renewable energy and embrace circular economy principles Continued Innovation : Stay tech forward , foster innovation culture and adapt to industry trends Market Domination and Global Expansion: Solidify European leadership, Explore global expansion and advocate for favourable regulations YEAR 1 YEAR 2 YEAR 3
- 6. DoloCon’s 3-year Roadmap for Pharma Revolution Year 1 : Laying the foundation | Year 2 : Technological advancements | Year 3 : Industry leadership YEAR 1 YEAR 2 YEAR 3 TECHNOLOGY MARKETING FINANCE OPERATIONS Supply-chain Diversification AI Inventory control AI & Analytics Personalized campaigns For patients AI Symptom Checker to assist doctors Predictive maintenance Optimize supplier contracts Cost impact analysis framework ML Marketing Customer data-driven Analysis Global production IoT Monitoring Drug R&D AI Innovation culture Tech ROI Sustainability practices Digital Brand AI marketing strategies Industry leader Global Reach Tech forefront AI-powered ecosystem Revenue targets Financial efficiency Tech for customer engagement Omni-channel marketing Logistic network optimization Tech. partnerships AI-driven care management for doctors AI-driven scheduling & planning Explore renewable energy for cost-effective electricity Govt. and industry collaboration for Favorable regulations Cost savings and growth via tech investments Competitive benchmarking Solvent recovery automation Agile production hubs for demand- based manufacturing Country-based distribution
- 7. Research & Drug Discovery Clinical Development Manufacturing & Supply Chain Commercialization & Launch Monitoring & Health Records Leverage AI-ML algorithm to analyze large datasets for potential drug candidates efficiently. Advanced screening to rapidly test compounds. Genomics & proteomics to identify novel drug targets. Rapid Prototyping of drug delivery systems. Telemedicine, remote monitoring & wearables for decentralized trials Adaptive trials to optimize trial design & outcomes in real-time biomarkers for patient stratification & treatment response prediction Real-world evidence to support trial outcomes 3D Printing & modular production systems Integrate IoT sensors and data analytics to optimize production processes and ensure quality control. Implement blockchain to enhance transparency, traceability & security Flexible manufacturing for personalized medicine Digital platforms to engage with doctors Platforms to provide patients with support, information & adherence Outcome-based pricing models for drugs Strategies to navigate complex reimbursement and regulations for timely access to market Interoperable electronic health records Integrate wearable devices and IoT sensors to collect real-time patient data to manage disease & treatment optimization AI for disease prediction Develop algorithms to guide treatment decisions and adjust therapies Growth Opportunities Emerging Tech Advanced Analytics, AI & ML Technologies Virtual Reality & Augmented Reality Blockchain for traceability Wearable & digital health devices Data Analytics & Real World Evidence Internet of things & connected devices Tech-Centric Value Chain Analysis Enhancing Business Potential through Value Chain Analysis for Strategic Growth Exploration Identifying Tech-based growth opportunities across pharmaceutical value chain
- 8. Recommendation Disease Management Disease Treatment Disease Diagnosis Telemedicine Prevention Online Portals Remote Patient Monitoring IoT based Devices Patient Care Platform Diagnostic Devices Lab Free Diagnosis Medical Devices Genetic & molecular diagnostics based personalized medicine Robotic Prosthetics IoT based personalized Surgery platforms AI & cloud-based platforms Predictive Diagnosis & wearables Remote Disease Testing Personalization Biomedical Sensor based Diagnostics Point of care diagnostics Enabled telemedicine Health & wellness wearables Omnichannel ordering Digital Network connecting Healthcare stakeholders Enhanced relationship with Stakeholders Faster commercialization Modernized IT Department Resilient Back office Operations Supply chain Control tower Business Outcomes Predictive Algorithms Data Ingestion DevOps Automation AI, ML IoT, AR/VR Digital Cloud Advanced Analytics Cyber Security Tech-enabled Patient Lifecycle Digital app to boost patient engagement with scheduled medicine delivery & notifications for disease management devices & remote monitoring. Comprehensive Cloud Strategy P P.E.E.R Framework to engage healthcare professionals Segmented communication, tailored content & digital webinars. E E-learning platforms, Mobile app for clinical guidance, VR surgery demo Education E Virtual Advisory boards, fund non- profit efforts & hospital CSR Engagement R Virtual reality networking, collaborative research efforts Relationship Engage consultants of e-pharmacies to nudge them to recommend DoloCon pharma products to patients to improve e-commerce revenue. Recommendation Tech-Based Solutions to Pursue Growth Opportunities Enhance Patient Lifecycle | Cloud Migration | Engage Healthcare Professionals
- 9. Political Stability & Regulatory Landscape Technological & economic developments INDIA SOUTH KOREA BRAZIL SAUDI ARABIA • AI: New drug development & discovery & personalized treatment • Telemedicine: Enhanced delivery through platforms & digital solutions • Growing pharma market, increased healthcare needs • Healthcare IT: Investment in IT like EMRs & health-data analytics • AI & Robotics: Used in drug discovery, diagnosis & manufacturing • Aging population & rising disposable income • Bio-technology- High investment in bio-technology capabilities & vaccine • Genomics & 3D printing: Used to develop new drugs • Local production & volatility are major affecting factors • Nanotechnology: Development of new drug delivery systems • Stem cell therapy: Used to treat a variety of diseases, including cancer • Increased healthcare spending & government support • Diverse transport modes: facilitates efficient distribution • Strategic Location: India's geographical location makes it a gateway to key markets • Designated SEZs • Advanced infrastructure: Well- developed transportation & logistics • Efficient customs procedures that can expedite the movement of goods. • Local manufacturing potential: Brazil local logistics costs are comparatively higher but has well- developed road & rail networks • Abundant natural resources • Investment in logistics technology • Government initiatives: Saudi government is promoting local pharmaceutical manufacturing and export-oriented industries. • Investment in Infrastructure: Saudi Arabia is investing in infrastructure, including ports and transport network Attractiveness Logistics & Transportation • Taxation: State, corporate, central taxes, common GST tax • Regulations: Bureaucratic & complex, improving EoDB • One of the largest economies, Pharma & manufacturing hub, highly influential consumer base • Taxation: Progressive tax system with income-based tax rates. • Regulations: Stringent in industries like pharmaceuticals • Advanced technology, popular cultural exports- high global presence • Taxation Policies: IRPJ, CSLL, PIS etc apply on pharma industry • Regulations: GMP, Anvisa & clinical trials for safety • Diverse economy, major commodities exporters with strength in mining & energy • Taxation Policies: SCT, VAT, and Import Duty affect prices, demand, and costs. • Regulations: SFDA, set GMP restrictions & registration & licensing for safety • Major oil exporter, working on diversifying economy Assessment of alternative supply network landscape and trade routes (1/2) Market/Supply Chain attractiveness across India, South Korea, Brazil & Saudi Arabia
- 10. Countries Risk & Challenges Overall score India Regulatory compliances & infrastructure gaps Quality control & IP protection 6/10 South Korea Higher costs & language & cultural barriers Limited local raw materials & smaller market 7/10 Brazil History of corruption & poor climate Economic instability & business differences 8/10 Saudi Arabia Tough cultural factors & disruptions in supply Underdeveloped local manufacturing units 8/10 Conclusion: After synthesizing all risks, India seems to be the country with the lowest risk & maximum potential Countries Competitor Market potential CODB Overall score India 300,00 High Low High South Korea 200,000 Medium Medium Moderate Brazil 100,000 Medium Medium Low-Moderate Saudi Arabia 50,000 Low High Low Conclusion: Considering overall competitive picture based on 3 factors, India even though with fragmented structure has the highest potential & lowest cost Countries Cost of labour Efficiency Export Opp. Overall score India 10 5 10 25/30 South Korea 6 10 6 22/30 Brazil 8 7 8 23/30 Saudi Arabia 4 9 7 20/10 *Given numbers according to quantitative & qualitative analysis of reports & research papers The Indian market provides significant growth opportunities for the pharma industry. However, for the industry to sustain a robust growth rate of 15–20% till 2020, DoloCon will have to rethink the way they have been doing business. Global Market Share’23 45% 7% Assessment of alternative supply network landscape and trade routes (2/2) Score calculation across various parameters to judge EODB for a pharma company